Menu Close
Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate
If you need more information please contact us, a member of the team will text you back as soon as possible.
1400 112th Ave SE,
Suite 100, Bellevue,
Washington 98004
info@arscience.com
Arscience Bio 2023
